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INTRODUCTION 
 
 Diabetes mellitus refers to a group of common metabolic disorders 
that  share the phenotype of hyperglycemia .The prevalence of type 2 
diabetes mellitus is increasing   rapidly  accounting  for 90-95 percent of 
the total diabetic population  
 Diabetes leads to a number of potentially disabling macro- and 
micro-vascular complications. Microvascular complications of diabetes 
include diabetic retinopathy (DR), diabetic nephropathy (DN), and 
diabetic peripheral neuropathy (DPN). Zinc plays a important role in both 
type 1 and type 2 diabetes (T2D). Serum zinc level is associated with 
Type 2 diabetes mellitus, and loss-of-function mutations in zinc 
transporter-8 gene protect against Type 2 Diabetes mellitus1,2. 
        The development of microvascular complications in diabetes is 
majorly due to oxidative stress. Zinc has an  antioxidative effect .Also it 
is a key component of many antioxidases. Lipid peroxidation induced 
damage is inhibited by zinc.Zinc induces the clearance of free radicals.3 
This suggest that zinc deficiency may be associated with the development 
of microvascular complications in diabetes mellitus 
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AIM & OBJECTIVES 
1) AIM OF THE STUDY 
 The purpose of this study was to analyze the relationship between 
zinc level and each diabetic microvascular complication and identify the 
features related to low serum zinc level.  
2) OBJECTIVES OF THE STUDY  
 To assess the serum zinc levels in subjects with type 2 diabetes 
mellitus. 
 To compare zinc levels in each microvascular complications. 
 To correlate between the zinc levels and microvascular 
complications. 
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REVIEW OF LITERATURE 
 Diabetes mellitus (DM) refers to a group of common metabolic 
disorders that share the phenotype of hyperglycemia. There are several 
distinct types of diabetes mellitus which are caused by number of factors  
like genetic and environmental factors . 
 
CLASSIFICATION 
 DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia, as opposed to earlier criteria such as age of onset or type 
of therapy. There are two broad types of DM, designated type 1 and  
type 2.  
 Type 1 Diabetes Mellitus is the result of complete or near-total 
insulin deficiency. Although type 1 DM most commonly develops before 
the age of 30, an autoimmune beta cell destructive process can develop at 
any age. It is estimated that between 5 and 10% of individuals who 
develop Diabetes mellitus after age 30 years have type 1 Diabetes 
Mellitus 4. 
 
 Type 2 Diabetes Mellitus is a heterogeneous group of disorders 
characterized by variable degrees of insulin resistance, impaired insulin 
secretion, and increased glucose production. Distinct genetic and 
metabolic defects in insulin action and/or secretion are identified in type 
 
4
2 DM4. Although type 2 DM more typically develops with increasing 
age, it is now being diagnosed more frequently in children and young 
adults,particularly in obese adolescents.Type 2 DM is preceded by 
impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) 
OTHER TYPES OF DM 
 Other etiologies for DM include specific genetic defects in insulin 
secretion or action, metabolic abnormalities that impair insulin secretion, 
mitochondrial abnormalities, and a host of conditions that impair glucose 
tolerance. 
 Maturity-onset diabetes of the young (MODY) and monogenic 
diabetes are subtypes of diabetes mellitus with an autosomal dominant 
inheritance, early age of onset (usually <25 years;), and impaired insulin 
secretion. 
  Pancreatic exocrine disease leads to DM when the majority of 
pancreatic islets are destroyed. Eg. Cystic fibrosis–related DM. 
Hormones  antagonizing insulin action also lead to DM. And so DM is 
often a feature of endocrinopathies such as acromegaly and Cushing’s 
disease. Viral infections also cause pancreatic islet destruction but are an 
extremely rare cause of DM. A form of acute onset of type 1 diabetes, 
termed fulminant diabetes, has been noted in Japan and may be related to 
viral infection of islet4 
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EPIDEMIOLOGY 
            Diabetes mellitus is the ninth major cause of death. About 1 in 11 
adults worldwide now have DM. Asia accounts for a major proportion of 
the rapidly emerging Type 2 Diabetes mellitus global epidemic. China 
and India  tops the list..Global burden of diabetes is more than 425 
million people.with one third of people older than 65 years and 82 million 
people in south east asia and 72 million in India.This  number is expected 
to rise to 629 million by 2045. The incidence of diabetes is  on a  
increasing trend due to lifestyle changes and food habits. 
 There is much geographic variation in the incidence of diabetes 
mellitus. The prevalence also varies among different ethnic 
populations.The developing regions of the world  like the African, Asian, 
and South American regions  account for 77 percentage of diabetics5,6,7 
The prevalence of DM is similar in both sexes.  Diabetes accounts for one 
in four health care dollars in the U.S. Diabetics , on average, have 
expenditures ∼2.3 times higher than expenditures of non diabetics. 
Criteria for the Diagnosis of Diabetes Mellitus9 
•  Symptoms of diabetes plus random blood glucose 
concentration ≥11.1 mmol/L (200 mg/dL) or 
•  Fasting plasma glucose ≥7.0 mmol/L (126 mg/dL) or 
 
7
•  Hemoglobin A1c ≥ 6.5%c or 
•  2-h plasma glucose ≥11.1 mmol/L (200 mg/dL) during an oral 
glucose tolerance test 
REGULATION OF GLUCOSE HOMEOSTASIS 
 
 Glucose homeostasis is a balance between hepatic gluconeogenesis 
and peripheral glucose uptake and utilization. The most important 
regulator of this equilibrium is insulin. Other regulators are  neural 
mechanisms , metabolic signals and  various hormones (e.g., glucagon) . 
Glucose homeostasis is also influenced by factors like leptin, adiponectin, 
resistin, irisin etc. 
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Regulation of glucose homeostasis. The organs shown contribute to 
glucose utilization, production, or storage. 
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INSULIN BIOSYNTHESIS 
        The beta cells of the pancreatic islets secrete insulin. Insulin is 
synthesized   initially as preproinsulin.. Preproinsulin is a eighty six –
aminoacid polypeptide. Proteolytic processing of this poly peptide give 
rise to proinsulin which  generates the C peptide and the A (21amino 
acids) and B (30 amino acids) chains of insulin.. The mature insulin 
molecule and C peptide are stored together and co-secreted from 
secretory granules in the beta cells.  
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INSULIN SECRETION 
 
          The key regulator of insulin secretion by the pancreatic beta cell is 
insulin. Insulin secretion is also influenced by amino acids, ketones, 
various nutrients, gastrointestinal peptides, and neurotransmitters. Insulin 
synthesis is stimulated when glucose levels are greater than 70mg/dl , 
primarily by enhancing protein translation and processing.   
 The process of insulin secretion starts with glucose entry into the 
beta cell. Glucose is transported into the beta cell by a facilitative glucose 
transporter. After which glucose phosphorylation  by  glucokinase  occur. 
Metabolism of glucose-6-phosphate subsequently, through glycolysis 
produces ATP. This inhibits the activity of an ATP-sensitive K+ channel. 
Inhibition of potassium channel produces beta cell membrane 
depolarization, which opens voltage-dependent calcium channels and 
leads to insulin secretion4.  
 There is a pulsatile pattern of hormone release, with small 
secretory bursts occurring about every 10 min, superimposed upon 
greater amplitude oscillations of about 80–150 min. Incretins are released 
from neuroendocrine cells of the gastrointestinal tract following food 
ingestion and amplify glucose-stimulated insulin secretion and suppress 
glucagon secretion. 
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Mechanisms of glucose-stimulated insulin secretion 
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Actions of Insulin
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                         Spectrum of glucose homeostasis and DM 
 
PATHOGENESIS 
TYPE 2 DIABETES MELLITUS  
  Insulin resistance and abnormal insulin secretion leads to the 
development of type 2 DM. Although the primary defect is 
controversial,most studies support the view that insulin resistance 
precedes an insulin secretory defect but that diabetes develops only when 
insulin secretion becomes inadequate4. 
 
GENETIC CONSIDERATIONS 
 Type 2 DM has a strong genetic component. The concordance of 
type 2 DM in identical twins is between 70 and 90% 4. Individuals with a 
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parent with type 2 DM have an increased risk of diabetes. if both parents 
have type 2 DM, the risk approaches 40%.  
 Insulin resistance, as demonstrated by reduced glucose utilization 
in skeletal muscle, is present in many nondiabetic, first-degree relatives 
of individuals with type 2 DM. Genetic polymorphisms have also been 
found in the genes encoding the PPARγ, K+ channel , Insulin receptor 
substrates etc.4 
Pathophysiology 
  Type 2 Diabetes mellitus has impaired insulin secretion, insulin 
resistance, excessive gluconeogenesis in liver, and abnormalities in lipid 
metabolism. Obesity, particularly visceral or central , is a very common 
accompainement of type 2 DM. In the early stages of the disorder, inspite 
of insulin resistance glucose tolerance remains normal , because the 
pancreatic beta cells compensate by increasing insulin output. 
 As insulin resistance and compensatory hyperinsulinemia progress, 
the pancreatic islets are not able to withstand the hyperinsulinemic state. 
IGT, characterized by elevations in postprandial glucose, then develops. 
A further decrease in  secretion of insulin and an increase in hepatic 
gluconeogenesis  lead to overt diabetes with fasting hyperglycemia. 
Ultimately, beta cell failure ensues.  
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Metabolic Abnormalities  
Abnormal muscle and fat metabolism 
             Insulin resistance, the decreased ability of insulin to act on target 
tissue is a marked feature of type 2 Diabetes mellitus .This results from a 
combination of genetic susceptibility and obesity. Insulin resistance 
affects glucose utilization by insulin-sensitive tissues and increases 
hepatic glucose output. Both effects contribute to the hyperglycemia. 
 Increased hepatic glucose output predominantly accounts for increased 
FPG levels, whereas decreased peripheral glucose usage results in 
postprandial hyperglycemia. 
IMPAIRED INSULIN SECRETION  
 Insulin secretion and sensitivity are interrelated. In type 2 DM, 
insulin secretion initially increases in response to insulin resistance to 
maintain normal glucose tolerance. Initially, the insulin secretory defect 
is mild and selectively involves glucose-stimulated insulin secretion, 
including a greatly reduced first secretory phase. The response to other 
nonglucose secretagogues, such as arginine, is preserved, but overall beta 
function is reduced by as much as 50% at the onset of type 2 Diabetes 
Mellitus. 
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 INCREASED HEPATIC GLUCOSE AND LIPID PRODUCTION 
 In type 2 DM, insulin resistance in the liver reflects the failure of 
hyperinsulinemia to suppress gluconeogenesis, which results in fasting 
hyperglycemia and decreased glycogen storage by the liver in the 
postprandial state. Increased hepatic glucose production occurs early in 
the course of diabetes, although likely after the onset of insulin secretory 
abnormalities and insulin resistance in skeletal muscle. As a result of 
insulin resistance in adipose tissue, lipolysis and free fatty acid flux from 
adipocytes are increased, leading to increased lipid lipoprotein synthesis 
in hepatocytes. 
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Insulin Resistance Syndromes 
 The insulin resistance condition comprises a spectrum of disorders, 
with hyperglycemia representing one of the most readily diagnosed 
features. The metabolic syndrome, the insulin resistance syndrome, and 
syndrome X are terms used to describe a constellation of metabolic 
derangements that includes insulin resistance, hypertension, dyslipidemia, 
central or visceral obesity, type 2 DM or IGT/IFG,  
         Mutations in the insulin receptor that interfere with binding or 
signal transduction are a rare cause of insulin resistance. Acanthosis 
nigricans and signs of hyperandrogenism (hirsutism, acne, and 
oligomenorrhea in women) are also common physical features. Polycystic 
ovary syndrome (PCOS) is a common disorder that affects 
premenopausal women and is characterized by chronic anovulation and 
hyperandrogenism. Insulin resistance is seen in a significant subset of 
women with PCOS, and the disorder substantially increases the risk for 
type 2 DM, independent of the effects of obesity. 
 Two distinct syndromes of severe insulin resistance have been 
described in adults: (1) type A, characterized  by severe 
hyperinsulinemia, obesity, and features of hyperandrogenism; and (2) 
type B characterized by severe hyperinsulinemia, features of 
hyperandrogenism, and autoimmune disorders  
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ROLE OF ZINC IN DIABETES AND IN MICROVASCULAR 
COMPLICATIONS  
 Zinc plays a major role in the development of both type 1 and type 
2 diabetes (T2D). Studies have shown that serum zinc level is associated 
with T2D, and loss-of-function mutations in zinc transporter-8 gene 
protect against T2D. 
 Zinc has a number of useful effects in both types of diabetes 
mellitus. (1O-13). This has been shown in many In-vitro and in-vivo studies 
in animals and humans. Decreased serum zinc levels and increased 
urinary excretion is known to be present in patients with both types of 
diabetes mellitus 15,16 . 
                TBARS is a marker of oxidative stress. Levels are high diabetic 
patients, and are reduced by zinc supplementation.11,15 Se-GPx was  low 
in patients with type-1 diabetes. With supplementation of zinc ,levels of 
Se-GPx returned to normal levels11.   Antioxidant enzymes like catalase, 
GPx and super-oxide dismutase (SOD) are reduced in diabetes induced 
animal models. 17-19 
              Supplementation of zinc in these animals increased the enzyme 
activity17-19. Metallothionein (MT) protein (an antioxidant ) synthesis in 
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the pancreatic islets, kidneys, liver and heart of diabetes-induced animals 
,significantly increased after supplementation of zinc. 19,20,21-2 
                     Zinc supplementation reduces renal oxidative damage and also 
downregulates expression of pro-fibrosis mediators in diabetics mediated 
via the expression of MT25. 
 MDA  levels is an index of lipid peroxidation. It was increased in 
diabetic animals. 18,20  Supplementation of zinc markedly reduced MDA 
levels.Zinc supplementation increases insulin sensitivity and action of 
antioxidants. 11,26 
              Rats simultaneously treated with a single injection of alloxan and 
Zinc chloride  showed  that hyperglycemia induced by alloxan  was 
significantly reduced at 24, 48, and 72 h post-treatment with Zinc 
chloride27. ZnCl injection also accentuated  glutathione in retina, pancreas 
and liver.  
 Zinc supplementation increases TNF-α gene expression in post 
menopausal diabetics. This suggests a interaction between Zinc 
homeostasis and oxidative stress28.  MT synthesis is increased by zinc 
supplementation and therby has a beneficial effect in diabetic neuropathy  
by reducing oxidative stress 29. 
 
22
 Zinc supplementation inhibited hyperglycemia induce cell death by 
decreasing reactive oxygen species production, facilitated via Nrf2 up-
regulation in renal tubular epithelial cells. 30.Studies reveal that diabetes 
is commonly accompanied by decrease in serum zinc levels and increased 
zinc excretion.31,32  
 Zinc supplementation improves glycemic control and promotes 
healthy lipid parameters 33.  
             
  
Proposed mechanism of zinc effect on oxidative stress and inflammation. Zinc 
attenuates oxidative damage and inflammation via MT, Cu/Zn SOD, Zn-finger 
protein, and itself 
  
 
23
Zinc transporter facilitates anti-apoptotic signaling 
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        α-glucosidase activity in the intestines is inhibited by zinc. 35,36. In skeletal 
muscles Zinc-α2-glycoprotein stimulates the phosphorylation of  
AMP-activated protein kinase (AMPKα) and increases cellular GLUT4 
protein37. This increase in the expression of the GLUT4 has also been observed 
in adipose tissue with resultant increase in glucose uptake 38,39.  
  Zinc Finger Protein 407 (ZFP407) is known to facilitate insulin 
stimulated glucose uptake via glucose transporter-4.40,41. Zinc also increased 
glucose transport in adipocytes, independent of insulin42-44. 
  Zinc stimulates the phosphorylation of the InsulinReceptor beta 
subunit42. Zinc also inhibits Glycogen synthase kinase and therby increases 
glycogen synthesis43. 
  In human pancreatic islet cells, Zinc transporter 8 is the key protein 
which plays a major role in both Zinc accumulation in insulin-containing 
vesicles and regulation of insulin secretion45-49. ZnO nanoparticles at dose 
70ng/ml reduced oxidative stress and improved pancreatic function 50. 
Intracellular Zinc inhibits glucagon secretion 51.  
 Human Islet Amyloid Polypeptide (hIAPP) (a polypeptide 
hormone secreted from pancreatic β-cells in response to glucose) and is 
cleared by the peptidases in the kidney. hIAPP is known to aggregate in 
the pancreas to form dense, insoluble extracellular fibrillar deposit, 
causing β-cell destruction in type-2 diabetes  
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 Zinc, significantly inhibits hIAPP amyloid fibrillogenesis at   
concentrations similar to those found in-vivo extracellular environments . 
This probably explains the linkage between the  mutations of SLC30A8 
zinc transporter (Zinc Transporter 8 [ZnT8]), which transports Zinc into 
the secretory granules, and type-2 diabetes.  
                  When ZnT8 absent mice were fed a control diet, glucose 
tolerance and insulin sensitivity were normal. However, after high-fat diet 
feeding, these mice became glucose intolerant or diabetic, and islets 
became less responsive to glucose. ZnT8 is downregulated on exposure to 
metabolic stress associated with diabetic and pre-diabetic states, 
suggesting that it might further contribute to progression of type-2 
diabetes.  
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 In β-cell specific SLC30A8 deficiency (ZnT8 knockout mice) a 
low peripheral blood insulin levels was observed, due to a substantial 
amount of the insulin being degraded during its first passage through the 
liver. 
 This is possibly due to the low level of Zinc in the portal 
circulation co-secreted by β-cells, due to the absence of ZnT8 (reducing 
uptake of Zinc by β-cells), which leads to augmented hepatic insulin 
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clearance. The ZnT8 is also downregulated in response to exposure of 
pancreatic β-cells to hypoxia, resulting in lowered cytosolic Zn 
concentrations. 
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 Pancreatic islet cells harvested from rats conditioned under 
intermittent hypoxia showed a significant reduction in Zinc Influx 
Transporter 8 (ZIP8) expression in the β-cell membrane, with resultant 
reduction in cellular Zinc concentration and insulin production  
  ZIP6 and ZIP7 function as two important zinc influx transporters 
to regulate cytosolic Zinc concentrations and insulin secretion in β-cells 
and ZIP-6 is also capable of directly interacting with GLP-1R to facilitate 
the protective effect of GLP-1 on β-cell survival . 
 Zip4 protein is located in human pancreaticβ-cells, is important for 
the accumulation of Zinc in the cytosol and granules of β-cells . Other 
Zinc transporters like ZnT3 and ZIP7 might also play a role in insulin 
secretion and glucose metabolism  
 L-type voltage-gated Ca channels and TRMP3 (transient receptor 
potential cation channel subfamily M member 3) are also in part 
responsible for Zinc transport into β-cells, which is also dependent  upon 
the metabolic status of the cell . Culture of rat pancreatic islets in either 
low or high vs. intermediate glucose concentrations triggers early 
mitochondrial oxidative stress and late β-cell apoptosis with loss of 
glucose stimulated insulin secretion. 
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 It is well known that Reactive Oxygen Species (ROS) can cause 
pancreatic β-cell death. This occurs due to the activation of Transient 
Receptor Potential Melastatin2 (TRPM2) channels by ROS. TRPM2 
causes Ca influx into the β-cells causing release of lysosomal Zinc, which 
results in β-cell death  
 In glucagon producing α-cells of the pancreas Zinc accumulates 
under low and high glucose conditions through both Ca channels and 
other Zinc transporting mechanisms, and the intracellular Zinc inhibits 
glucagon secretion . Furthermore during hypoglycemia the principal 
signal that initiates glucagon secretion could be the detection by α-cells of 
a sudden decrease in Zinc paralleling the fall in insulin in the islet peri-
portal circulation and this drop in concentration of Zinc, closes α-cell ion 
channels, promoting entry of calcium which stimulates glucagon 
secretion  
 Zinc-α2-glycoprotein is gaining increasing recognition as a marker 
of insulin resistance in type-2 diabetes. Zinc-α2-glycoproteins are also 
involved in lipid metabolism, affecting the expression of several lipolytic 
enzymes at hepatic and adipose tissue level.  Zinc supplementation 
reduces Fasting Blood Glucose, 2 h Post Prandial Blood Glucose and 
HbA1c in patients with diabetes, as well as reducing total cholesterol, 
LDL cholesterol and triglycerides in both patients with and without 
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diabetes]. The above molecular/enzymatic level mechanisms probably 
explain the beneficial effects of Zinc supplementation on glycaemic 
control and lipids observed in humans 
              Zinc supplementation increases the activity and levels of key 
antioxidant enzymes and proteins, while lowering lipid peroxidation. 
Oxidative stress also plays a important role in the pathogenesis of both 
micro- and macro-vascular complications of diabetes 52.. Increased 
formation of AGEs leads to diabetes related complications 52. Zinc 
supplementation markedly inhibited the formation of advanced 
glycosylation end products.  
 COMPLICATIONS OF DIABETES MELLITUS 
 
          Diabetes leads to varied complications which affect many organ 
systems and majority of morbidity and mortality associated with the 
disease is attributed to its complications. Strikingly, in the United States, 
diabetes is the leading cause of new blindness in adults, renal failure, and 
non traumatic lower extremity amputation4.  
           Diabetes-related complications usually appear after the second 
decade of hyperglycemia. Many individuals with type 2 DM have 
complications at the time of diagnosis because of the long asymptomatic 
period of  increased blood sugars.  
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 Diabetes-related complications can be divided  into  vascular   and    
nonvascular complications. 
 The diabetic vascular complications are microvascular 
(retinopathy, neuropathy, nephropathy) and macrovascular complications 
(coronary heart disease [CHD], peripheral arterial disease [PAD], 
cerebrovascular disease). Microvascular complications are diabetes-
specific. Macrovascular complications are similar to those in nondiabetics 
but occur at greater frequency in individuals with diabetes4. 
Gastroparesis, infections, skin changes, and hearing loss are non vascular 
complications. 
  The risk of dementia or impaired cognitive function is whether 
increased by type 2 diabetes is not clear 
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 Microvascular complications of DM include diabetic retinopathy, 
diabetic nephropathy and diabetic peripheral neuropathy. 
DIABETIC RETINOPATHY 
 DM is the leading cause of blindness between the ages of 20 and 
74 in the United States. Diabetics are 25 times more likely to become 
legally blind than individuals without DM.  Progressive diabetic 
retinopathy and clinically significant macular edema leads to severe 
vision loss  
 
Pathogenesis  
 Aldose reductase plays a important role in the development of 
diabetes complications. Aldose reductase is the initial enzyme in the 
intracellular polyol pathway, which involves the conversion of glucose 
into sorbitol. Hyperglycemia increase the flux of sugar molecules through 
the polyol pathway, leading to sorbitol accumulation in cells. sorbitol 
accumulation leads to osmotic stress mechanism which leads to diabetic 
retinopathy.4  
 
          Hyperglycemia can stimulate free radical production and reactive 
oxygen species formation leading to cellular injury 
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         Growth factors, like vascular endothelial growth factor (VEGF),  
TGF β etc have been found to play major roles in the development of 
diabetic retinopathy4 
 Diabetic retinopathy is generally classified as either background or  
proliferative.Background retinopathy includes such features as small 
hemorrhages in the middle layers of the retina. They clinically appear as 
“dots” and therefore are frequently referred to as “dot hemorrhages.” 
Hard exudates are caused by lipid deposition that typically occurs at the 
margins of hemorrhages 
 Microaneurysms are small vascular dilatations that occur in the 
retina, often as the first sign of retinopathy4. Retinal edema may result 
from microvascular leakage and is indicative of compromise of the blood-
retinal barrier. The appearance of neovascularization in response to 
retinal hypoxemia is the hallmark of proliferative diabetic retinopathy4. 
 These newly formed vessels appear near the optic nerve and/or 
maculaand rupture easily, leading to vitreous hemorrhage, fibrosis, and 
ultimately retinal detachment 
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Diabetic retinopathy with scattered hemorrhages, yellow exudates and 
neovascularization 
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  It is well known that hyperglycemia accelerates the formation of 
advanced glycation end products (AGEs), which have been implicated in 
the pathogenesis of DR 53. They can stimulate ROS production in retinal 
pericytes, largely via activation of NADPH oxidase, which results in 
retinal pericyte apoptosis 54. It is suggested that Zn might prevent retinal 
pericyte apoptosis via inhibition of NADPH oxidase in DR.. 
 Ocular neovascularization, which is most potently caused by 
hypoxia and ischemia, is also a key component in DR 55,56. It has been 
convincingly demonstrated that hypoxia inducible factor-1 (HIF-1) and 
VEGF are involved in the initiation and progression of neovascularization 
in DR 57. Zn reduces inflammatory cytokine production by upregulating 
the Zn-finger protein, A20, which inhibits NF-κB activation via the 
TRAF pathway 58.  In addition, recent finding suggests that ZnT8 
expression was reduced by ischemic insults and to restore the ZnT8 to its 
basal homeostatic levels can prevent retinas from ischemia induced injury 
59 
 
 
 
37
 
 Proposed mechanism by which zinc protects from DR. Zinc protects DR 
by suppressing the pericyte apoptosis, capillary leakage, and neovascularization. 
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DIABETIC NEPHROPATHY 
 
 Diabetic nephropathy is the leading cause of chronic kidney 
disease (CKD), ESRD, and CKD requiring renal replacement therapy. 
Albuminuria in individuals with DM is associated with an increased risk 
of cardiovascular disease. Individuals with diabetic nephropathy 
commonly have diabetic retinopathy. The mechanisms by which chronic 
hyperglycemia leads to diabetic nephropathy, although poorly defined, 
involve the effects of factors like angiotensin II, renal microcirculation 
changes , and structural changes in the glomerulus4 
 
               The nephropathy associated with diabetes has been attributed to 
oxidative stress 8. Oxidative stress can be caused either by the increased 
production of reactive oxygen species (ROS) or a deficiency in 
antioxidant defense. Antioxidant deficiency can result from low intake of 
vitamins, such as vitamin C and E, or impaired synthesis of enzymes, 
such as super oxide dismutase, catalase and glutathione peroxidase, due 
to zinc deficiency 6. Chronic zinc deprivation generally results in an 
increased sensitivity to the effects of oxidative stress due to deficiency of 
these enzymes7. 
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HISTOPATHOLOGICAL   CHANGES
  
 The nephropathy that develops in type 2 DM differs from that of 
type 1 DM in the following respects: (1) microalbuminuria or 
macroalbuminuria may be present when type 2 DM is diagnosed, 
reflecting its long asymptomatic period; (2) hypertension more commonly 
accompanies microalbuminuria or macroalbuminuria in type 2 DM; and 
(3) microalbuminuria may be less predictive of diabetic nephropathy and 
likelihood of progression to macroalbuminuria in type 2 DM. albuminuria 
in type 2 DM may be secondary to factors unrelated to DM, such as 
hypertension, congestive heart failure (CHF), prostate disease, or 
infection. 
 Because some individuals with type 1 or type 2 DM have a decline 
in GFR in the absence of albuminuria, annual measurement of the serum 
creatinine to estimate GFR should also be performed. An annual 
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microalbuminuria measurement (albumin-to-creatinine ratio in spot urine) 
is advised in individuals with type 1 or type 2 DM 
 Screening for albuminuria should commence 5 years after the onset 
of type 1 DM and at the time of diagnosis of type 2 DM. Type IV renal 
tubular acidosis (hyporeninemic hypoaldosteronism) may occur in type 1 
or 2 DM. These individuals develop a propensity for hyperkalemia and 
acidemia,.   
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DIABETIC NEUROPATHY 
 Diabetic neuropathy occurs in ~50% of individuals with long-
standing type 1 and type 2 DM.  Polyneuropathy, mononeuropathy and/or 
autonomic neuropathy are the different manifestations.The presence of 
CVD, elevated triglycerides, and hypertension is also associated with 
diabetic peripheral neuropathy. 
 The most common form of diabetic neuropathy is distal symmetric 
polyneuropathy4. Symptoms may include a sensation of numbness, 
tingling, sharpness, or burning that begins in the feet and spreads 
proximally. Pain typically involves the lower extremities, is usually 
present at rest, and worsens at night4. As diabetic neuropathy progresses, 
the pain subsides and eventually disappears, but a sensory deficit in the 
lower extremities persists. Physical examination reveals sensory loss, loss 
of ankle deep-tendon reflexes, and abnormal position sense. 
 Mononeuropathies most commonly invove the median, ulnar, and 
radial nerves. Mononeuropathy is less common than polyneuropathy in 
DM and presents with pain and motor weakness in the distribution of a 
single nerve. 
 Mononeuropathies can occur at entrapment sites such as carpal 
tunnel or be noncompressive.Mononeuropathy multiplex may also occur. 
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Involvement of the third cranial nerve is most common and is heralded by 
diplopia. Other cranial nerves, such as IV, VI, or VII may be affected. 
 Diabetic polyradiculopathy is a syndrome characterized by severe 
disabling pain in the distribution of one or more nerve roots. It may be 
accompanied by motor weakness. Intercostal or truncal radiculopathy 
causes pain over the thorax or abdomen. Involvement of the lumbar 
plexus or femoral nerve may cause severe pain in the thigh or hip and 
may be associated with muscle weakness in the hip flexors or extensors 
(diabetic amyotrophy). Fortunately, diabetic polyradiculopathies are 
usually self-limited and resolve over 6–12 months. 
Autonomic Neuropathy 
 Individuals with long-standing type 1 or 2 DM may develop signs 
of   autonomic dysfunction involving the cholinergic, noradrenergic, and   
peptidergeric systems. DM-related autonomic neuropathy can involve 
multiple systems, including the cardiovascular, gastrointestinal, 
genitourinary, sudomotor, and metabolic systems.  
         Autonomic neuropathies affecting the cardiovascular system cause a 
resting tachycardia and orthostatic hypotension. Gastroparesis and 
bladder emptying abnormalities are often caused by the autonomic 
neuropathy seen in DM. Hyperhidrosis of the upper extremities and 
anhidrosis of the lower extremities result from sympathetic nervous 
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system dysfunction. Anhidrosis of the feet can promote dry skin with 
cracking, which increases the risk of foot ulcers.  
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 Zinc supplementation ameliorate severity of neuropathy symptoms 
in diabetic patients with mild to moderate peripheral neuropathy 24. Zinc 
supplementations alone have also also demonstrated a significant 
improvement in motor nerve conduction velocity following 
supplementation in patients with type-2 diabetes 28.  
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1) Ying Ying Luo et al conducted a study in Peking University 
People's Hospital, Beijing, China, in 412 hospitalized patients with 
type 2 diabetes mellitus. The serum zinc levels between patients 
with specific microvascular complications and those without were 
compared. The association between zinc level and each 
microvascular complication. were analyzed. And concluded that 
lower serum zinc level in T2D patients lead to microvascular 
complications.Also hypozincemia is an independent risk factor for 
DN60. Older age, longer diabetes duration, higher HbA1c level, and 
the prevalence of DN were risk factors related to the lower serum 
zinc level60. 
2)  Xiao Miao et al,Weixia Sun et al in a study conducted in The 
Second Hospital of Jilin University, China concluded that increased 
oxidative stress plays an important role in many human diseases, such as 
diabetes and its complication. Zn supplementation seems beneficial for 
the patients with diabetes to control glucose levels. Zn as an antioxidant 
or via induction of MT attenuates ROS effect61. Zn might protect retina 
from ROS induced pericytes apoptosis, capillary leakage, and 
neovascularization , thereby might have protective on DR61. 
3) Migdalis IN et al, Triantafilou P et al, conducted a study in NIMTS 
Hospital, Athens, Greece in seventy-seven patients with Type 2 
 
49
diabetes (39 neuropathic and 38 non-neuropathic) and 38 control 
subjects and demonstrated a negative relationship between zinc 
level and lipid peroxidation and concluded diabetic neuropathy 
with low zinc level may be due to the elevated lipid peroxidation63. 
4):   Dhia J., TimimiDhia et al did a study in the College of Medicine, 
University of Duhok, Iraq with 300 diabetic patients and 100 non-
diabetic healthy subjects. The serum zinc levels in diabetic patients 
were compared to non-diabetic control subjects. Low- serum zinc 
was present in one third of patients with diabetic nephropathy, 
particularly among patients with microalbuminuria64. Low serum 
zinc levels leads to advancing nephropathy64.  
 5) Study of Zinc and Glycated Hb Levels in Diabetic Complications 
by B. Jyothirmayi et al, Department of Biochemistry, SRM 
Medical College Hospital & Research Centre, Kattankulathu 
showed that correlation of HbA1C and zinc was inversely related 
and diabetic complications were attributed to increased 
susceptability to lipid peroxidation due to free radical damage68. 
Strict glycemic control and zinc supplimentations can prevent 
complications to some extent. 
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MATERIALS AND METHOD 
Study design : Cross-sectional comparative study 
Study period :  6 months 
Study area   : Govt. Kilpauk Medical College ,Chennai. 
Sampling    :  Simple random sampling  
 
 Study population:-  
 Diabetic patients attending the Medicine Department, Govt. Kilpauk 
Medical College, Chennai. 
 Sample Size  
          Sample size is calculated using the formula 
           (1.96)² pq/ d² Considering the prevalence a  with CI 95% and 
power 80%  Sample size =120 
 Inclusion criteria:-  
 Type 2 diabetic patients in the age group of 40-65 yrs  
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 Exclusion criteria:- 
         Patients suffering from  
  hypertension 
 alcoholics, patients with Vit B12 deficiency  
 with history of acute infections and thyroid dysfunction  
 with auto immune diseases  
  on chemotherapy  
 non diabetic renal disease  
 patients with macrovascular complications CAD,CVA,PVD      
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METHODOLOGY 
         After getting consent from patient or patiemt’s relatives, following 
data will be collected from all diabetic patients. 
 
         Name, gender, age, duration of diabetes, treatment details including 
oral hypoglycemic drugs and insulin and detailed clinical examination 
will be done.  
     
 Diabetes was defined using the World Health Organization criteria:  
(1) random plasma glucose ≥11.1 mmol/L(200mg/dl);  
                 or 
(2) fasting plasma glucose ≥7.0mmol/L (126 mg/dl); 
               or  
(3) 2h glucose level in oral glucose tolerance test ≥11.1 
mmol/L(200md/dl). 
         
Fasting and Post Prandial blood sugars were done. 
Zinc level was assayed by atomic absorption spectrophotometer.  
MACHINE AND MODEL NO: Perkin Elmer 800AA. 
REFERENCE RANGE 70-150 microgm/dl 
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Diabetic Retinopathy was diagnosed ophthalmologically by fundus 
examination. 
Diabetic Nephropathy was by diagnosed by urinary protein/creatinine 
ratio. DN diagnosed if the urinary PCR was higher than.3. Urinary 
infection and other types of nephropathy were excluded during the 
diagnosis of DN.  
Diabetic Neuropathy was diagnosed based on the results of physical 
examination and nerve conduction study. 
 
 The data of each patient will be collected in specific proforma 
(ANNEXURE 2) which includes patient’s name, age, sex, 
demographic details, presenting complaints, risk factors and all 
clinical data.  
 All the relevant data and values are then entered in master chart in 
Microsoft excel format an then analyzed statiscially. 
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STATISTICAL ANALYSIS 
 
 The data was collected in the master chart obtained in the 
Microsoft excel format. 
 Descriptive statistics was done for all data and were reported in 
terms of mean values and percentages. Suitable statistical tests of 
comparison were done. Continuous variables were analysed with the 
unpaired t test and ANOVA. Categorical variables were analysed with 
the Chi-Square Test and Fisher Exact Test. Pearsons r correlation was 
done to assess relationship between variables. Statistical significance was 
taken as P < 0.05. The data was analysed using SPSS version 16 and 
Microsoft Excel 2007. 
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RESULTS 
 The total patients recruited in our study were 120. The following 
chart depict frequency distribution of gender. 
 
GENDER: 
 In a total of 120 patients participated in our study 67 patients were 
males and 53 patients were females. This distribution shows the 
predominance of males in type 2 diabetes mellitus. 
 
Gender distribution 
 
Male
56%
Female
44%
GENDER FREQUENCY PERCENTAGE 
MALE 67 55.8 
FEMALE 53 44.2 
TOTAL 120 100.0 
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ASSOCIATION BETWEEN SERUM ZINC AND GENDER 
 
 
 
 Serum zinc levels when matched against gender status, it was 
observed that the mean serum zinc levels were 76.90±30.36 in male 
patients and 66.70±30.51 in female patients (p= 0.071). The data 
subjected to unpaired test reveals the existence of statistically non-
significant association between serum zinc distribution and gender (p > 
0.05). 
 
 
 
 
 
76.90
66.70
60.00
62.00
64.00
66.00
68.00
70.00
72.00
74.00
76.00
78.00
Male Female
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MEAN AND STANDARD DEVIATION OF VARIABLES: 
 
 
 Data collected from 120 selected T2DMsubjects were internally 
compared, tabulated, analysed and interpreted by using descriptive and 
inferential statistics based on the formulated objectives of the study. 56% 
of the study subjects were males. The mean age of the participants was 
52.21 ± 5.68 years, and the mean duration of diabetes was 8 years. Mean 
fasting blood sugar levels tabulated was 173.13±48.25 and mean post 
prandial. 
  
  N Mean Std. Deviation 
AGE 120 52.20 5.68
DM_DURATION 120 7.96 2.38
FBS 120 173.13 48.25
PPBS 120 218.07 55.43
ZINC 120 72.39 30.73
URINE PCR 120 0.52 0.89
VALID N (LISTWISE) 120     
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DISTRIBUTION OF AGE GROUP: 
Age group Frequency Percent 
<50 years 47 39.2%
50 to 60 years 67 55.8%
>61 years 6 5.0%
 
 
 
 
 
  
<50 years
39%
50 to 60 years
56%
>61 years
5%
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DISTRIBUTION OF DURATION OF DIABETES: 
 
Duration of Diabetes Frequency Percent 
<5 years 7 5.8% 
5 to 10 years 104 86.7% 
>10 years 9 7.5% 
 
 
 
  
<5 years
6%
5 to 10 years
87%
>10 years
7%
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CORRELATION BETWEEN SERUM ZINC AND DURATION 
OF DIABETES 
 In patients with T2DM, when the serum zinc levels was matched 
and correlated with duration of diabetes, the mean serum zinc level was 
72.39 μmol/L and the mean duration of diabetes was 7.96 years. The 
difference in values is statistically non-significant as the p value is 
0.301with a negative correlation as per person’s coefficient of -0.095. 
Blood sugar values were 218.07±55.43. Zinc levels exhibited values of 
72.39±30.73 and urine PCR exhibited values were 0.52±0.89. 85% of the 
subjects had normal fundus and 11% had NPDR. 39% of the study 
population had impaired nerve conduction studies. 
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ASSOCIATION BETWEEN S.ZINC AND URINE PCR 
 Serum zinc levels when matched against urine PCR status, it was 
observed that the mean serum zinc levels were 81.63±27.34 in normal 
urine PCR category and 35.46±4.34 in elevated urine PCRcategory 
(p=<0.0001). The data subjected to unpaired t test reveals the existence of 
statistically significant association between serum zinc distribution and 
urine PCRstatus (p < 0.05). 
 
CORRELATION BETWEEN SERUM ZINC AND URINE PCR 
 In patients with T2DM,when the serum zinc levels was matched 
and correlated with urine PCR levels, the mean urine zinc level was 72.39 
μmol/L and the mean urine PCR level was 0.52 g/mmol. The difference 
in values is statistically significant as the p value is < 0.0001with a 
negative correlation as per pearson’s coefficient of -0.479.  
 The decrease in serum zinc levels correlates negatively and 
strongly with the increase in urine PCR levels. The linear decrease in 
serum zinc level measurement in T2DM cases group in relation to 
increased urine PCR levels is true 48% of times. 
 For every 1 % decrease in serum zinc levels there is a 
corresponding 0.22 % increase in urine PCR levels. This is indicated by 
the linear correlation formula y = -0.0138x + 1.5169.  
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DISTRIBUTION OF RETINOPATHY 
 
DR Frequency Percent 
Normal 
102 85.0 
PDR 
5 4.2 
NPDR 
13 10.8 
Total 
120 100.0 
 
 Out of 120 patients in our study, 102 patients had normal 
fundus , 5 patients had PDR and 13 patients had NPDR. 
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DISTRIBUTION OF RETINOPATHY 
 
 
 
  
Normal
85%
PDR
4% NPDR11%
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ASSOCIATION BETWEEN SERUM ZINC LEVELS AND 
DIABETIC RETINOPATHY 
 
Serum zinc levels when matched against retinopathy status, it was it was 
observed that the mean serum zinc levels were 78.88±28.73 in normal 
fundus category, 32.00±2.00 in proliferative diabetic retinopathy category 
and 37.00±4.22 in non-proliferative diabetic retinopathy category 
(p=<0.0001). The data subjected to ANOVA test reveals the existence of 
statistically significant association between serum zinc distribution and 
presence/severity of retinopathy (p < 0.05). 
 
  
  N Mean 
Std. 
Deviation P value 
Normal 102 78.88 28.73 
<0.0001 
PDR 5 32.00 2.00 
NPDR 13 37.00 4.22 
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ASSOCIATION BETWEEN SERUM ZINC AND DIABETIC 
RETINOPATHY 
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DISTRIBUTION OF DIABETIC PERIPHERAL NEUROPATHY 
 
         NCS Frequency Percent 
Normal 73 60.8 
Impaired 47 39.2 
Total 120 100.0 
 
In a total of 120 patients 73patients had normal NCS and 47 had impaired 
NCS 
 
DISTRIBUTION OF PERIPHERALNEUROPATHY 
 
 
 
Normal
61%
Impaired
39%
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ASSOCIATION BETWEEN SERUM ZINC AND PERIPHERAL 
NEUROPATHY 
 
NCS N Mean 
Std. 
Deviation P value 
zinc Normal 73 93.44 17.35 
<0.0001 
Impaired 47 39.70 13.27 
 
 Serum zinc levels when matched against nerve conduction study 
status, it was observed that the mean serum zinc levels were 93.44±17.35 
in normal nerve conduction study patients, 39.70±13.27 in impaired nerve 
conduction study patients (p= <0.0001). The data subjected to chi squared 
test reveals the existence of statistically significant association between 
serum zinc distribution and nerve conduction study status (p < 0.05). 
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ASSOCIATION BETWEEN SERUM ZINC AND PERIPHERAL 
NEUROPATHY 
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DISCUSSION 
 In our study total of 120 patients were included. All patients were 
included in study after getting consent, detail history and physical 
examination and after ruling out the exclusion criteria. Out of 120 
patients 67 patients were male and 53 patients were females. This 
distribution shows the predominance of males in type2 diabetes mellitus.. 
The mean age of the participants was 52.21 ± 5.68 years, and the mean 
duration of diabetes was 8 years.. Zinc levels exhibited values of 
72.39±30.73 and urine PCR exhibited values were 0.52±0.89. 85% of the 
subjects had normal fundus and 11% had NPDR. 39% of the study 
population had impaired nerve conduction studies 
 
  In our study the distribution of mean serum zinc levels and the 
urine PCR status was meaningfully significant. This is evident by the 
decreased mean serum levels in elevated urine PCR category compared to 
normal urine PCR category (mean reduction difference of 46.14 
percentage points, 57% lower).  
  The same view was echoed in a study conducted by Al Timimi DJ 
et al  which showed that significantly low levels of e-GFR and high levels 
of microalbuminuria were observed in diabetic patients with low serum 
zinc level as compared to normal serum zinc level59. It concluded that  
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lower serum zinc levels leads to advancing nephropathy and indicated the 
need for determining serum zinc levels and the effectiveness of zinc 
supplementation in diabetic patients, particularly during the assessment of 
kidney damage59 
  Ying ying Lu et al in a study conducted in 412 patients concluded 
that zinc level was significantly lower in patients with elevated urinary 
albumin Creatinine ratio60.And also suggested that serum zinc level was 
an independent risk factor for DN. 
 
  Barman S et al explored whether zinc supplementation protects 
against diabetic nephropathy through modulation of kidney oxidative 
stress and stress-induced expression related to the inflammatory process 
in streptozotocin-induced diabetic rats61.This study concluded that  zinc 
supplementation has a significant beneficial effect in the control of 
diabetic nephropathy. Which was exerted through a protective influence 
on oxidative-stress-induced cytokines, inflammatory proliferation and 
consequent renal injury61. 
 
 On internal comparison the significant conclusion observed was 
that higher urine PCR status was related to decreased serum zinc levels 
(2.30 times more chance of developing elevated urine PCR). Lower zinc 
level is a good, consistent and direct predictor of high urine PCR or 
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diabetic nephropathy. Hence Lower serum zinc level can be considered as 
an independent risk factor for diabetic nephropathy. 
 In our study the distribution of mean serum zinc levels and the 
presence/severity of retinopathy status was meaningfully significant. This 
is evident by the decreased mean serum levels in non-proliferative 
diabetic retinopathy category compared to normal fundus category (mean 
reduction difference of 41.88percentage points, 53% lower) and 
decreased mean serum zinc levels in proliferative diabetic retinopathy 
category compared to non-proliferative diabetic retinopathy category 
(mean reduction difference of 5.00percentage points, 14% lower).  
       The same view was echoed in a study conducted in Peking 
University People's Hospital, Beijing, China, in 412 hospitalized patients 
with type 2 diabetes mellitus which concluded that lower zinc levels are 
found in DR patients than in those without DR , suggesting that zinc 
might play an important role in the development of DR60.  Also suggested 
that in T2D patients with a relatively low zinc level, the protective effect 
of the anti-oxidative zinc may be reduced, and the risk of DR may be 
elevated61. 
       A case control study conducted in 42 diabetic patients (14 without 
retinopathy [DC]; 14 with non-proliferative diabetic retinopathy [NPDR]; 
14 with proliferative diabetic retinopathy [PDR]) at Ebin Al-Haitham 
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Specialized Hospital, Baghdad, Iraq showed significant reductions in 
serum means of Zn and Zn/Cu ratios in all diabetic retinopaths as 
compared to DC. And concluded that both glycation and oxidative 
processes were involved in the development of diabetic retinopathy, and 
changes in the concentration of Zn  have some impact on the disease 
progression62. 
  Miao X et al concluded that Zn supplementation seems beneficial 
for the patients with diabetes to control complications. Zn as an 
antioxidant or via induction of MT attenuates ROS effect. Zn might 
protect retina from ROS induced pericytes apoptosis, capillary leakage, 
and neovascularization thereby might have protective on DR63.  
            On internal comparison the significant conclusion observed was 
that lower serum zinc level in Type 2 Diabetics patients was related to 
increased incidence of DR status (2.47 times more chance of developing 
diabetic retinopathy). Lower zinc level is a good,consistent and direct 
predictor of non-proliferative diabetic retinopathy and proliferative 
diabetic retinopathy. Hence lower serum zinc level can be considered as 
an independent risk factor for diabetic retinopathy 
 In our study the distribution of mean serum zinc levels and the 
nerve conduction study status was meaningfully significant. This is 
evident by the decreased mean serum levels in impaired nerve conduction 
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study category compared to normal nerve conduction study category 
(mean reduction difference of 53.74 percentage points, 58% lower).  
 The same view was echoed by  a double-blind study conducted by 
Hayee et al which showed that serum zinc levels at baseline are 
significantly lower in patients with diabetic neuropathy when compared 
with healthy controls. conduction velocity were altered significantly in 
patients who received zinc supplement and conducted that zinc therapy 
may lead to better glycemic control and improvement in DPN64.  
 Migdalis et al demonstrated a negative relationship between zinc 
level and lipid peroxidation65. Increased lipid peroxidation with low 
levels of zinc lead to neuropathy. 
 A double blind randomized study  conducted on 50 subjects by 
Gupta R et al  included 20 age and sex matched healthy controls ; 15 
patients of diabetes mellitus with neuropathy received placebo for 6 
weeks and 15 patients of diabetes mellitus with neuropathy were  
given supplemental zinc sulphate. It concluded that oral zinc 
supplementation helps in achieving better glycemic control and 
improvement in severity of peripheral neuropathy66. 
 On internal comparison the significant conclusion observed was 
that decreased serum zinc level in Type 2 diabetics was related to 
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increased incidence of impaired nerve conduction study status (2.35 times 
more chance of developing diabetic neuropathy). Lower zinc level is a 
good, consistent and direct predictor of diabetic neuropathy. Hence 
Lower serum zinc level can be considered as an independent risk factor 
for diabetic neuropathy. 
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CONCLUSION 
 
 We can conclude that: Age, gender and glycaemic parameters and 
duration of diabetes had no statistically significant role to play on 
analysing the relationship between serum zinc level and microvascular 
complications in patients with type 2 diabetes. 
 On internal comparison the following conclusions were observed  
o Lower zinc levels associated with abnormal linear increase 
in urine PCR levels 
o Linear and inverse relationship with urine PCR 
o Lower zinc levels associated with incidence of diabetic 
nephropathy 
o Lower zinc levels associated with incidence of diabetic 
neuropathy and retinopathy 
 This study is a hypothesis proving study. Hence results have high 
clinical significance. 
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PROFORMA 
 
 
Name:                                                          Age/sex:                                           
Address:                                                      OP NO: 
DM – Yes/No 
Diagnosis: 
 
QUESTIONNAIRE: 
Kuppusamy Socio economic status    : 
Duration of DM                                  : 
Type of treatment                               : 
History of hypertension                      : 
History of autoimmune diseases         : 
History of alcohol intake                    : 
History of non diabetic kidney disease: 
     
 
 
 
 
 
     INVESTIGATIONS: 
 FBS 
 PPBS 
 RFT  
 LFT                                                                                              
 Hb  
 Urine Protein 
 Urine sediment 
 Sr. zinc 
 NCS 
 Fundus examination. 
 
  
சுயஒப்ᾗதல் பᾊவம் 
ஆய்ᾫ ெசய்யப்பᾌம் தைலப்ᾗ: 
 
இடம்:           ெபாᾐ மᾞத்ᾐவத்ᾐவ ᾐைர 
                             அரசு  கீழ்பாக்கம் மᾞத்ᾐவ கல்ᾥாி மᾞத்ᾐவமைன 
                        ெசன்ைன 
 
பங்குெபᾠபவாின்  ெபயர் : 
பங்குெபᾠபவாின்  வயᾐ :                     பங்குெபᾠபவாின்  எண் : 
 
ேமேல குறிப்பிட்ᾌள்ள மᾞத்ᾐவ ஆய்வின் விவரங்கள் எனக்கு 
விளக்கப்பட்டᾐ.  நான் இவ்வாய்வில் தன்னிச்ைசயாக பங்ேகற்கிேறன்.  எந்த 
காரணத்தினாேலா எந்த சட்டசிக்கᾤக்கும் உட்படாமல் நான் இவ்வாய்வில் 
இᾞந்ᾐ விலகிக்ெகாள்ளல்லாம் என்ᾠம் அறிந்ᾐ ெகாண்ேடன். 
இந்த ஆய்ᾫ சம்பந்தமாகேவா,இைத சார்ந்ᾐ ேமᾤம் ஆய்ᾫ 
ேமற்ெகாள்ᾦம்ேபாᾐம் இந்த ஆய்வில்பங்கு ெபᾠம் மᾞத்ᾐவர் என்ᾔைடய 
மᾞத்ᾐவ அறிக்ைககைள பார்ப்பதற்கு என் அᾔமதி ேதைவயில்ைல என அறிந்ᾐ 
ெகாள்கிேறன்.  இந்த ஆய்வின் ᾚலம் கிைடக்கும் தகவைலேயா, ᾙᾊைவேயா 
பயன்பᾌத்திக்ெகாள்ள மᾠக்க மாட்ேடன். 
இந்த ஆய்வில் பங்கு ெகாள்ள ஒப்ᾗக்ெகாள்கிேறன்.   இந்த ஆய்ைவ 
ேமற்ெகாள்ᾦம் மᾞத்ᾐவ அணிக்கு உண்ைமᾜடன் இᾞப்ேபன் என்ᾠம் 
உᾠதியளிக்கிேறன். 
 
 
பங்ேகற்பவாின்   ைகெயாப்பம்                             ஆய்வாளாின்   ைகெயாப்பம் 
இடம் : 
ேததி : 
                       PATIENT CONSENT FORM 
 
Study detail:    “Relationship Between Serum Zinc Level and Microvascular 
Complications in Patients with Type 2 Diabetes’’ 
 
Study centre  :             KILPAUK  MEDICAL COLLEGE, CHENNAI 
Patients Name  : 
Patients Age  : 
Identification Number        : 
   Patient may check (     ) these boxes 
I  confirm that I have understood the purpose of procedure for the above study. I 
have the opportunity to ask question and all my questions and doubts have been 
answered to my complete satisfaction. 
I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as required 
under the law. I agree not to restrict the use of any data or results that arise from this 
study. 
I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well-being 
or any unexpected or unusual symptoms. 
I hereby consent to participate in this study. 
I hereby give permission to undergo complete clinical examination and diagnostic 
tests including hematological, biochemical, radiological tests. 
 
 
 
Signature/thumb impression:    
 
 
Patients Name and Address:                            place   date 
 
 
Signature of investigator :    
 
 
Study investigator’s Name :                               place   date      
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1 33 m l ip use nil married nil RTA 1 bilateral f,t,o 2 7 7 22 4 4
2 30 m l op nil nil married nil RTA 4 left t,p 2 14 10 24 5 5
3 29 m l ip nil nil married nil RTA 1 right f 2 8 7 20 2 2 yes
4 45 f l ip nil primary married nil fall 1 left f,t,p 2 10 7 17 5 16
5 57 m l ip use nil married nil RTA 1 left f,t,p 2 7 8 25 4 6
6 19 m l ip nil primary unmarried nil RTA 1 right t,p 2 8 7 18 5 7
7 32 m l ip nil nil married nil RTA 1 left f,t,p 2 9 7 20 6 3
8 45 m l ip nil nil married nil RTA 1 left t 2 12 9 21 7 2
9 45 m l ip nil primary married nil RTA 1 right t 1 13 7 16 6 4
10 35 m l ip nil nil married nil RTA 1 right p 1 9 7 18 5 3
11 38 m l ip nil degree married nil RTA 1 right p 1 8 7 19 8 4
12 40 m l ip nil nil married nil RTA 1 right t 2 10 8 20 4 11
13 42 m l ip nil nil married nil RTA 4 left f,t,p 2 8 7 19 2 3
14 30 m l ip nil degree married nil TTA 3 right f,t,p 3 12 9 22 3 6 organic 
catatonia
15 36 m l ip use nil married nil assault 1 left f,t 1 10 7 23 1 8 yes
16 75 f l ip nil primary married nil RTA 1 bilateral f 2 7 9 27 16 2
17 45 f l ip nil nil married nil RTA 1 left f, BG 2 8 8 26 17 4
18 47 m l ip nil nil married nil RTA 1 right f 2 9 7 21 9 12
19 44 f l ip nil primary married nil RTA 1 left t 1 19 12 20 5 6
20 41 m l ip use primary married nil RTA 1 right f 1 11 9 18 3 8
21 65 m l ip nil primary married nil fall 1 bilateral f,t,p 2 9 8 25 20 15
22 37 m l ip nil primary married nil RTA 1 right t 1 8 9 18 4 8
23 38 m l op nil nil married nil RTA 3 left f,p 1 12 10 19 4 7 yes
24 33 m l ip nil nil married nil RTA 1 left p 1 7 11 20 5 7
25 38 m l ip nil degree married nil RTA 1 left f,t 2 9 8 17 2 6
26 32 m l ip nil nil married nil RTA 1 left f,p 1 7 9 18 5 8
27 30 m l ip nil primary married nil RTA 1 bilateral f,p 2 8 10 20 12 5
28 29 m l ip nil primary married nil RTA 1 left t,p 1 11 12 21 4 9
29 43 m l ip nil nil married yes RTA 1 left t,p 3 22 9 19 3 12
30 38 m l ip use primary married nil RTA 1 left f 2 10 10 19 4 6
31 46 f l ip nil primary married nil RTA 1 bilateral f,t 2 8 7 22 8 4
32 49 f l ip nil nil married nil RTA 1 left f,t 1 7 9 20 6 9
33 45 f l ip nil nil married nil RTA 2 right o 2 10 8 19 3 17
34 37 f l ip nil primary married nil RTA 1 left f,p 2 11 13 17 4 7
35 42 f l ip nil primary married nil RTA 1 bilateral o 1 8 11 19 5 14
36 34 m l ip nil primary married nil RTA 1 right t,o 2 16 7 21 2 3
37 47 m l ip nil primary married nil RTA 1 right f 2 9 9 18 6 8
38 22 m l ip use nil unmarried nil RTA 2 bilateral f 2 14 8 19 5 11 yes
39 48 f l ip nil nil married nil RTA 1 right f,p 2 11 7 20 7 10
40 39 m l ip use primary married nil RTA 1 left t 2 10 11 21 9 8
41 20 m l ip use nil unmarried nil RTA 1 right f 1 8 10 19 3 9
42 35 f l ip nil primary married nil RTA 2 right t,p 2 9 12 17 5 16
43 47 m l ip nil nil married nil RTA 1 right f,t 1 7 7 21 7 8
44 35 m l ip use nil married nil RTA 1 left f,BG 2 7 8 18 14 8
45 42 f l ip nil primary married nil RTA 1 left p 1 7 19 17 6 9
46 42 f l ip nil nil married nil RTA 2 left p 2 8 10 19 4 16
47 33 m l ip nil nil married nil RTA 1 right f 1 10 7 21 5 7
48 37 m l ip nil nil married nil RTA 1 right p 1 7 7 20 4 5
49 66 m l ip use nil married yes fall 1 left f,p 3 8 14 28 21 16
50 61 m l ip nil nil married nil fall 1 right f 2 7 9 19 5 4
51 36 m l ip nil degree married nil RTA 1 right t 2 10 15 18 5 5
51 47 m l ip use nil married nil RTA 1 left f 2 7 8 20 4 3
53 58 m l ip nil nil married nil RTA 1 left t 2 8 9 21 5 5
54 38 f l ip nil primary married nil RTA 1 left f 2 10 8 27 17 7
55 51 f l ip nil nil married nil RTA 1 right o 1 7 7 19 6 4
56 58 f l ip nil nil married nil RTA 1 right f,p 2 8 9 18 4 14
57 57 m l ip use nil married nil RTA 1 left f,p 2 9 7 17 8 9
58 33 m l ip nil primary married nil RTA 1 right t,o 2 7 9 22 7 10
59 38 m l ip nil primary married nil RTA 1 right t,p 1 7 7 21 5 6
60 44 f l ip nil primary married nil RTA 1 bilateral f,p 1 7 11 20 9 8
61 43 m l ip use primary unmarried nil RTA 3 bilateral f 2 12 9 18 6 9 yes
62 49 m l ip nil primary married nil RTA 1 left p 2 9 8 17 7 5
63 58 m l ip nil primary married nil RTA 1 bilateral f,t,p 3 8 12 25 19 17
64 52 f l ip nil primary married nil RTA 1 right f 1 10 9 17 6 4
65 61 m l ip nil nil married nil fall 1 left f 2 8 7 16 5 7
66 58 m l ip nil nil married nil RTA 1 right f,p 2 10 14 18 12 4
67 55 f l ip nil nil married nil RTA 1 right t,p 1 8 9 17 4 6
68 21 m l ip use primary unmarried nil RTA 1 left f 2 8 8 21 5 3
69 36 m l ip nil primary married nil RTA 2 right f 2 9 9 22 3 15
70 44 m l ip nil nil married nil RTA 1 left t,p 2 7 8 16 2 5
71 28 m l ip use primary married nil assault 3 right f 1 13 10 18 6 8 yes
72 39 f l ip nil primary married nil RTA 1 left p 2 10 7 17 14 6
73 34 m l ip nil primary married nil RTA 2 left f 2 8 9 16 4 16
74 67 m l ip nil primary married nil RTA 1 left f,t 2 7 8 22 3 12
75 33 f l ip nil primary married nil RTA 1 left f 2 7 20 21 9 4
76 49 m l ip nil nil married nil RTA 1 right f,p 1 8 7 16 4 10
77 35 m l ip nil nil married nil RTA 1 bilateral f 1 10 9 17 8 5
78 29 f l ip nil degree unmarried nil RTA 1 right f 1 9 11 16 3 3
79 34 m l op use nil married nil RTA 3 left f,p 2 7 10 19 11 5
80 42 m l ip nil primary married nil RTA 1 right f,t,p 3 9 8 18 6 17
81 39 m l ip nil primary married nil RTA 1 left f,t 1 8 9 16 4 7
82 72 f l ip nil primary married nil fall 1 right f,p 2 7 7 18 10 4
83 44 f l ip nil primary married nil RTA 1 right f 1 20 11 17 2 5
84 57 m l ip use nil married nil RTA 3 right f 2 7 9 16 5 8
85 32 m l op nil nil married nil RTA 3 left f 2 8 9 17 4 6
86 46 f l ip nil nil married nil RTA 1 left f,t 2 8 7 19 7 9
87 44 m l ip nil nil married nil RTA 1 left f 2 10 7 20 5 6
88 57 m l ip nil nil married nil RTA 1 bilteral f,t,p 3 8 10 18 17 7
89 42 f l ip nil nil married nil RTA 1 left f 2 7 8 16 12 5
90 41 m l ip nil nil married nil RTA 1 right f 1 7 9 17 3 8
91 36 m l ip nil nil married nil RTA 3 left t,o 2 7 13 19 13 5
92 34 f l ip nil nil married nil RTA 3 left f,t 1 7 24 18 2 12
93 33 m l ip nil nil married nil RTA 1 left f 2 8 9 17 10 4
94 28 m l ip use nil unmarried nil RTA 1 right f 1 7 12 20 5 7
95 65 f l ip nil nil married nil RTA 2 left f,p 2 7 9 23 14 15
96 33 m l ip use degree married nil RTA 1 right f,t 1 7 11 16 6 6
97 39 m l ip nil primary married nil RTA 1 right f 1 7 10 18 9 5
98 31 m l ip use nil married nil RTA 1 right f 1 7 9 17 4 12
99 38 f l ip nil degree married nil RTA 1 left f 2 8 8 22 15 6
100 27 m l ip nil primary unmarried yes RTA 1 left t 1 7 9 16 5 3
S.NO. AGE SEX
Duration of DM 
(in yrs)
FBS 
(mg/dl)
PPBS 
(mg/dl)
SERUM ZINC 
(µg/dl) URINE PCR
fundus 
examinati
on NCS
1 52 F 8 202 232 86 0.12 Normal normal
2 42 F 3 186 211 90 0.2 Normal normal
3 40 M 3.5 103 196 100 0.08 Normal normal
4 61 M 10 170 191 88 0.15 Normal normal
5 48 F 6 154 189 95 0.26 Normal normal
6 47 M 7 132 186 102 0.13 Normal normal
7 58 F 10 130 192 87 0.14 normal normal
8 65 M 7 240 300 106 0.22 normal normal
9 58 M 5 212 245 110 0.28 normal normal
10 60 M 15 179 312 83 0.2 normal normal
11 45 F 2 110 140 115 0.13 normal normal
12 55 F 8 211 203 36 0.26 normal impaired
13 53 F 8 106 210 40 0.12 normal impaired
14 51 M 10 201 237 98 0.16 normal normal
15 47 M 7 146 150 96 0.17 normal normal
16 54 M 5 192 200 32 0.4 normal impaired
17 53 F 12 241 323 40 0.45 normal impaired
18 55 f 8 106 163 100 0.12 normal normal
19 58 f 10 211 262 38 0.6 npdr impaired
20 60 f 6 213 182 41 1.2 npdr normal
21 48 f 7 104 145 118 0.13 normal normal
22 53 M 8 96 133 107 0.2 normal normal
23 50 M 10 85 140 118 0.16 normal normal
24 54 M 8 162 183 118 0.22 Normal normal
25 50 M 10 176 209 104 0.12 Normal normal
26 49 M 7 132 201 98 0.22 normal normal
27 51 M 10 201 182 86 0.28 normal normal
28 55 M 4 180 173 101 0.16 normal normal
29 48 M 8 200 201 98 0.24 normal normal
30 60 M 12 211 187 103 0.23 normal normal
31 50 M 9 243 212 94 0.16 normal normal
32 58 M 6 132 163 106 0.26 normal normal
33 52 M 7 165 180 90 0.14 normal normal
34 51 M 9 132 174 89 0.16 normal normal
35 42 F 6 183 265 35 0.13 normal normal
36 55 M 10 160 270 30 1.2 NPDR impaired
37 53 M 9 133 173 101 0.13 normal impaired
38 45 M 9 160 203 43 0.12 normal impaired
39 60 M 9 145 226 38 0.22 normal impaired
40 54 M 7 256 280 32 1.8 npdr impaired
41 45 M 10 133 160 40 0.2 normal impaired
42 56 M 8 145 213 36 0.1 normal impaired
43 45 M 6 256 246 42 0.26 normal impaired
44 60 F 9 133 201 45 0.22 normal impaired
45 50 M 6 201 173 35 0.1 normal impaired
46 59 F 8 146 256 38 3 npdr impaired
47 56 F 12 180 353 40 2.3 npdr impaired
48 50 M 10 153 193 88 0.12 normal normal
49 50 F 11 270 380 30 4 pdr impaired
50 41 M 7 133 180 88 0.12 normal normal
51 59 M 11 260 342 34 4 pdr impaired
52 46 M 6 143 176 102 0.24 normal normal
53 50 M 8 243 301 41 3 npdr impaired
54 52 F 7 132 182 98 0.12 normal normal
55 53 M 4 179 201 89 0.16 normal normal
56 42 F 15 121 153 114 0.22 normal normal
57 60 M 12 132 182 101 0.26 normal normal
58 59 F 9 180 233 98 0.12 normal normal
59 51 F 7 123 176 106 0.13 normal normal
60 46 F 12 198 289 30 0.6 pdr impaired
61 60 F 12 154 201 97 0.22 normal normal
62 46 F 6 169 198 88 0.1 normal normal
63 45 M 7 143 178 82 0.21 normal normal
64 63 F 10 201 263 42 2.1 npdr normal
65 52 F 8 132 201 110 0.12 normal normal
66 58 M 9 142 232 39 0.26 normal impaired
67 60 M 10 201 288 30 0.4 npdr impaired
68 50 M 8 232 268 34 3 pdr impaired
69 42 F 9 243 152 102 0.1 normal normal
70 51 F 10 143 267 34 1.2 npdr impaired
71 44 M 11 164 245 36 0.6 npdr normal
72 49 M 8 110 197 108 0.12 normal normal
73 54 F 14 265 301 40 3 npdr normal
74 59 M 10 157 200 114 0.17 normal normal
75 40 M 5 132 187 98 0.12 normal normal
76 54 M 8 156 188 96 0.12 normal impaired
77 52 M 7 233 276 39 0.22 normal impaired
78 47 M 9 176 201 101 0.12 normal normal
79 49 F 9 132 182 88 0.21 normal normal
80 60 F 11 153 190 40 0.16 normal impaired
81 55 F 5 156 190 37 0.27 normal impaired
82 60 M 10 160 207 35 0.18 normal impaired
83 56 F 7 154 198 88 0.16 normal normal
84 52 F 9 132 176 85 0.12 normal normal
85 41 F 6 214 300 34 0.23 normal impaired
86 52 F 9 201 231 96 0.11 normal normal
87 57 F 10 126 170 89 0.24 normal normal
88 55 F 8 187 259 45 0.23 normal impaired
89 65 M 5 282 332 30 0.21 normal impaired
90 60 F 10 201 233 42 0.21 normal impaired
91 58 F 7 133 183 44 0.1 normal impaired
92 45 F 6 179 201 40 0.22 normal impaired
93 49 F 8 183 267 38 0.13 normal impaired
94 50 F 4 400 450 30 3 normal impaired
95 55 F 6 298 350 32 3.5 pdr impaired
96 53 F 5 259 365 39 0.2 npdr impaired
97 58 M 6 199 280 42 0.22 normal impaired
98 48 F 8 163 183 37 0.13 normal impaired
99 42 M 9 170 221 41 0.16 normal impaired
100 49 M 8 156 189 88 0.12 Normal normal
101 48 F 7 133 180 98 0.09 normal normal
102 52 M 6 143 187 100 0.12 normal normal
103 51 M 7 176 201 88 0.16 normal normal
104 47 M 6 187 234 98 0.23 normal normal
105 55 M 9 145 187 90 0.2 normal normal
106 53 M 6 176 204 96 0.15 normal normal
107 54 M 9 167 189 101 0.1 normal normal
108 58 M 7 178 198 108 0.25 normal normal
109 51 M 5 134 176 86 0.08 normal normal
110 49 M 5 143 187 95 0.17 normal normal
111 57 M 6 156 200 99 0.27 normal normal
112 45 F 4 243 254 36 0.46 normal impaired
113 54 M 7 176 201 43 0.33 normal impaired
114 50 F 4 165 234 89 0.23 normal normal
115 52 F 7 178 199 100 0.1 normal normal
116 56 F 6 134 178 96 0.2 normal normal
117 49 F 9 145 189 91 0.26 normal normal
118 51 F 8 123 179 88 0.12 normal normal
119 48 M 9 145 176 33 2.1 normal impaired
120 59 M 8 176 201 35 3.1 normal impaired
